Australian pharmaceutical manufacturer IDT says it is beginning to show tangible signs of recovery after a period of leadership change and financial pressure, reporting improved earnings and renewed operational momentum in the first half of the financial year 2026.
IDT signals turnaround as revenue rises and losses narrow under strategic reset
February 18, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Scientists identify highly specific targets that could transform multiple myeloma treatment
March 15, 2026 - - Australian Biotech -
Australians turn to local pharmacies as frontline of everyday healthcare
March 13, 2026 - - Latest News -
Sandoz and Camp Quality unite to strengthen support for Australian families facing childhood cancer
March 13, 2026 - - Latest News -
The leadership challenge behind Australia’s medicine access gap
March 13, 2026 - - Latest News -
Australia’s top community pharmacists honoured at national awards
March 13, 2026 - - Latest News -
Australia has spent four decades having the wrong conversation about medicines access
March 13, 2026 - - Latest News -
‘An absolute medical miracle’ - MPs highlight progress and challenges at Cystic Fibrosis event
March 13, 2026 - - Latest News

